

Global Sedation Drugs and Companies Pipeline Review H2 2016

Sedation Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, September 1, 2016 /EINPresswire.com/ --
Summary

'[Sedation](#) - Pipeline Review, H2 2016', provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.



WISE GUY RESEARCH
CONSULTANTS PVT LTD

Complete report details @ <https://www.wiseguyreports.com/reports/619268-sedation-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619268-sedation-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Sedation
- The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
- The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route

of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sedation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sedation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619268-sedation-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sedation Overview 7

Therapeutics Development 8

Pipeline Products for Sedation - Overview 8

Sedation - Therapeutics under Development by Companies 9

Sedation - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Sedation - Products under Development by Companies 13

Sedation - Companies Involved in Therapeutics Development 14

AstraZeneca Plc 14

Drawbridge Pharmaceuticals Pty Ltd 15

Jiangsu Nhwa Pharmaceutical Corporation Ltd. 16

NanoMedex Pharmaceuticals, Inc. 17

Paion AG 18

Primex Pharmaceuticals Oy 19

The Medicines Company 20

Therakind Limited 21

Sedation - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration	27
Assessment by Molecule Type	29
Drug Profiles	30
ABP-700 - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
ADV-6209 - Drug Profile	32
Product Description	32
Mechanism Of Action	32
R&D Progress	32
alphaxalone - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
clonidine hydrochloride - Drug Profile	35
Product Description	35
Mechanism Of Action	35
R&D Progress	35
EL-001 - Drug Profile	36
Product Description	36
Mechanism Of Action	36
R&D Progress	36
propofol - Drug Profile	37
Product Description	37
Mechanism Of Action	37
R&D Progress	37
propofol microemulsion - Drug Profile	38
Product Description	38
Mechanism Of Action	38
R&D Progress	38
remimazolam - Drug Profile	39
Product Description	39
Mechanism Of Action	39
R&D Progress	39
Small Molecule to Agonize GABA-A for Sedation - Drug Profile	45
Product Description	45
Mechanism Of Action	45
R&D Progress	45
Sedation - Dormant Projects	46
Sedation - Discontinued Products	47
Sedation - Product Development Milestones	48
Featured News & Press Releases	48
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy	48
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy	49

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619268

Norah Trent

wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.